Clinical trials
Completed Phase 3 trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,162 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 4 |
| 2002 | 8 |
| 2003 | 21 |
| 2004 | 27 |
| 2005 | 46 |
| 2006 | 89 |
| 2007 | 110 |
| 2008 | 119 |
| 2009 | 82 |
| 2010 | 102 |
| 2011 | 80 |
| 2012 | 44 |
| 2013 | 44 |
| 2014 | 37 |
| 2015 | 31 |
| 2016 | 39 |
| 2017 | 42 |
| 2018 | 37 |
| 2019 | 46 |
| 2020 | 42 |
| 2021 | 35 |
| 2022 | 26 |
| 2023 | 28 |
| 2024 | 14 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,162 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 82 |
| AstraZeneca | 73 |
| Eli Lilly and Company | 67 |
| Novo Nordisk A/S | 65 |
| Boehringer Ingelheim | 58 |
| GlaxoSmithKline | 52 |
| Sanofi | 50 |
| Pfizer | 38 |
| Hoffmann-La Roche | 24 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 21 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 161 |
| Diabetes Mellitus | 71 |
| Breast Neoplasms | 37 |
| Pulmonary Disease, Chronic Obstructive | 37 |
| Carcinoma, Non-Small-Cell Lung | 29 |
| Schizophrenia | 27 |
| Asthma | 23 |
| Arthritis, Rheumatoid | 22 |
| Epilepsy | 21 |
| Dyslipidemias | 19 |
Trials
Showing 1 to 25 of 1,162. Each trial links to its page on Pharma Observatory.
1,062 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.